Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jul 22;15(7):2005.
doi: 10.3390/pharmaceutics15072005.

Next-Generation Nanomedicine Approaches for the Management of Retinal Diseases

Binapani Mahaling  1 , Shermaine W Y Low  1 , Sanjay Ch  2 , Utkarsh R Addi  1 , Baseer Ahmad  1 , Thomas B Connor  1 , Rajiv R Mohan  3 , Swati Biswas  2 , Shyam S Chaurasia  1   4
Affiliations
Review

Next-Generation Nanomedicine Approaches for the Management of Retinal Diseases

Binapani Mahaling et al. Pharmaceutics. .

Abstract

Retinal diseases are one of the leading causes of blindness globally. The mainstay treatments for these blinding diseases are laser photocoagulation, vitrectomy, and repeated intravitreal injections of anti-vascular endothelial growth factor (VEGF) or steroids. Unfortunately, these therapies are associated with ocular complications like inflammation, elevated intraocular pressure, retinal detachment, endophthalmitis, and vitreous hemorrhage. Recent advances in nanomedicine seek to curtail these limitations, overcoming ocular barriers by developing non-invasive or minimally invasive delivery modalities. These modalities include delivering therapeutics to specific cellular targets in the retina, providing sustained delivery of drugs to avoid repeated intravitreal injections, and acting as a scaffold for neural tissue regeneration. These next-generation nanomedicine approaches could potentially revolutionize the treatment landscape of retinal diseases. This review describes the availability and limitations of current treatment strategies and highlights insights into the advancement of future approaches using next-generation nanomedicines to manage retinal diseases.

Keywords: nanodelivery; nanodevices; nanomedicines; nanoparticles; nanostructured scaffolds; retina.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

Figures

Figure 1
Figure 1
Schematic diagram depicting next-generation nanomedicine for the management of retinal diseases.
See this image and copyright information in PMC

References

    1. Duvvuri S., Majumdar S., Mitra A.K. Drug delivery to the retina: Challenges and opportunities. Expert Opin. Biol. Ther. 2003;3:45–56. doi: 10.1517/14712598.3.1.45. - DOI - PubMed
    1. Thapa R., Khanal S., Tan H.S., Thapa S.S., van Rens G.H.M.B. Prevalence, Pattern and Risk Factors of Retinal Diseases Among an Elderly Population in Nepal: The Bhaktapur Retina Study. Clin. Ophthalmol. 2020;14:2109. - PMC - PubMed
    1. Mahaling B., Low S.W.Y., Beck M., Kumar D., Ahmed S., Connor T.B., Ahmad B., Chaurasia S.S. Damage-Associated Molecular Patterns (DAMPs) in Retinal Disorders. Int. J. Mol. Sci. 2022;23:2591. doi: 10.3390/ijms23052591. - DOI - PMC - PubMed
    1. Chaurasia S.S., Lim R.R., Lakshminarayanan R., Mohan R.R. Nanomedicine Approaches for Corneal Diseases. J. Funct. Biomater. 2015;6:277. doi: 10.3390/jfb6020277. - DOI - PMC - PubMed
    1. Bourne R.R.A., Steinmetz J.D., Saylan M., Mersha A.M., Weldemariam A.H., Wondmeneh T.G., Sreeramareddy C.T., Pinheiro M., Yaseri M., Yu C., et al. Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: The Right to Sight: An analysis for the Global Burden of Disease Study. Lancet Glob. Health. 2021;9:e144–e160. doi: 10.1016/S2214-109X(20)30489-7. - DOI - PMC - PubMed

LinkOut - more resources